medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-164Research ArticleСтатьиЛечение ожирения у больных с нарушениями менструальной функцииTreatment of obesity in patients with menstrual dysfunctionВедзижеваЭ. Р.VedzizhevaE. R.noemail@neicon.ruКузнецоваИ. В.KuznetsovaI. V.noemail@neicon.ruУспенскаяЮ. Б.UspenskayaYu. B.noemail@neicon.ruФГБОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I. M. SechenovRussian Federation201701042017210Современная гинекология4853Copyright © Ведзижева Э.Р., Кузнецова И.В., Успенская Ю.Б., 20172017Ведзижева Э.Р., Кузнецова И.В., Успенская Ю.Б.Vedzizheva E.R., Kuznetsova I.V., Uspenskaya Y.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/164

Ожирение является распространенным заболеванием и часто сопровождается нарушениями менструальной функции и фертильности. Патогенез нарушений менструальной функции у больных ожирением и возможности его коррекции недостаточно изучены. Целью настоящего исследования стало изучение влияния комбинации сибутрамина и метформина на метаболические параметры и эндокринную функцию репродуктивной системы женщин с ожирением. В результате проведенного исследования была установлена более высокая распространенность репродуктивных нарушений у больных ожирением с дислипидемиями. Сравнительный анализ антропометрических, метаболических и репродуктивных параметров на фоне лечения выявил преимущества комплекса сибутрамин + метформин по сравнению с методом коррекции образа жизни.

Obesity is a common disease and is often accompanied by impairment of menstrual function and fertility. The pathogenesis of menstrual dysfunction in obese patients and the possibility of its correction have not been sufficiently studied. The purpose of this study was to study the effect of the combination of sibutramine and metformin on the metabolic parameters and endocrine function of the reproductive system of obese women. As a result of the study, a higher prevalence of reproductive disorders in obese patients with dyslipidemia was established. Comparative analysis of anthropometric, metabolic and reproductive parameters against the background of treatment revealed the advantages of the sibutramine + metformin complex compared with the method of lifestyle correction.

ожирениеинсулинорезистентностьдислипидемиялептингрелиннарушения менструального цикласибутраминметформинobesityinsulin resistancedyslipidemialeptinghrelinmenstrual irregularitiessibutraminemetforminReferencesApovian C.M. Obesity: definition, comorbidities, causes, and burden. Am.J. Manag. Care. 2016; 22: 176-185.Apovian C.M. Obesity: definition, comorbidities, causes, and burden. Am.J. Manag. Care. 2016; 22: 176-185.Румянцева С. А., Оганов Р. Г., Ступин В. А., и др. Проблемы и перспективы коррекции промежуточного метаболизма у больных с сосудистой коморбидностью. Рациональная фармакотерапия в кардиологии. 2013; 9 (3): 316-322.Румянцева С. А., Оганов Р. Г., Ступин В. А., и др. Проблемы и перспективы коррекции промежуточного метаболизма у больных с сосудистой коморбидностью. Рациональная фармакотерапия в кардиологии. 2013; 9 (3): 316-322.Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq. Bras. Endocrinol. Metabol. 2009; 53 (2): 262-270.Coutinho W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arq. Bras. Endocrinol. Metabol. 2009; 53 (2): 262-270.Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum. Reprod. 2007; 22: 414-420.Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. Hum. Reprod. 2007; 22: 414-420.van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum. Reprod. 2008; 23: 324-328.van der Steeg JW, Steures P, Eijkemans MJ, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum. Reprod. 2008; 23: 324-328.Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction 2010; 140: 347-364.Brewer CJ, Balen AH. The adverse effects of obesity on conception and implantation. Reproduction 2010; 140: 347-364.Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007; 59 (2): 151-184.Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007; 59 (2): 151-184.Выдрыч А.Н. Ожирение в практике врача-гинеколога: клинический случай. Consilium medicum. 2015; 6; 17: 54-60.Выдрыч А.Н. Ожирение в практике врача-гинеколога: клинический случай. Consilium medicum. 2015; 6; 17: 54-60.Ou HT, Chen PC, Wu MH. Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. J. Formos. Med. Assoc. 2017; 116 (2): 80-89.Ou HT, Chen PC, Wu MH. Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. J. Formos. Med. Assoc. 2017; 116 (2): 80-89.Wang M, Tong JH, Zhu G et al. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr. Res. 2012; 138: 54-57.Wang M, Tong JH, Zhu G et al. Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study. Schizophr. Res. 2012; 138: 54-57.Van Mil EG, Westerterp KR, Kester AD, Dele-marre-van de Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolescents. J. Clin. Endocrinol. Metab. 2007; 92 (4): 1409-1414.Van Mil EG, Westerterp KR, Kester AD, Dele-marre-van de Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolescents. J. Clin. Endocrinol. Metab. 2007; 92 (4): 1409-1414.Bennett WL, Odelola OA, Wilson LM et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann. Intern. Med. 2012; 156: 27-36.Bennett WL, Odelola OA, Wilson LM et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann. Intern. Med. 2012; 156: 27-36.Firouzjaei A, Li GC, Wang N et al. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr. Diabetes. 2016; 6: e209.Firouzjaei A, Li GC, Wang N et al. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr. Diabetes. 2016; 6: e209.Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol Diabetes Obes. 2014; 21 (5): 323-329.Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol Diabetes Obes. 2014; 21 (5): 323-329.Nawrocka-Rutkowska J, Ciecwiez S, Mar-ciniak A et al. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria - impact of metformin treatment. Ann. Agric. Environ. Med. 2013; 20 (3): 528-532.Nawrocka-Rutkowska J, Ciecwiez S, Mar-ciniak A et al. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria - impact of metformin treatment. Ann. Agric. Environ. Med. 2013; 20 (3): 528-532.Le T, Flatt SW, Natarajan L et al. Effects of Diet Composition and Insulin Resistance Status on Plasma Lipid Levels in a Weight Loss Intervention in Women. J. Am. Heart Assoc. 2016; 5 (1).Le T, Flatt SW, Natarajan L et al. Effects of Diet Composition and Insulin Resistance Status on Plasma Lipid Levels in a Weight Loss Intervention in Women. J. Am. Heart Assoc. 2016; 5 (1).

The authors declare that there are no conflicts of interest present.